top of page


Integrating the multiple breath washout test into international multicentre trials

Clare Saunders, Renee Jensen, Paul D. Robinson, Sanja Stanojevic, Michelle Klingel, Christopher Short, Jane C. Davies, Felix Ratjen 

A Short extension to multiple breath washout provides additional signal of distal airway disease in people with CF: A pilot study

Christopher Short , Thomas Semple, Clare Saunders , Dominic Hughes , Samantha Irving , Laura Gardener, Mark Rosenthal , Paul D Robinson, Jane C Davies

Evaluation of a multiple breath nitrogen washout system in children

Sarah Issac, Renee Jensen, Pinelopi Anagnostopoulou, Jane C. Davies, Monika Gappa, Phillip Latzin, Clare Saunders, Christopher Short, Florian Singer, Sanja Stanjevic, Annelies Zwitseroot, Felix Ratjen 

Horses for courses: Learning from functional tests of pulmonary health?

Developments in multiple breath washout testing in children with cystic fibrosis

Clare Saunders, Katie Bayfield, Samantha Irving, Christopher Short, Andrew Bush, Jane C. Davies

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Jane C. Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, R. Scott Harris, Daniel Campbell, Neil Ahluwalia, Christopher Short, Eric Haseltine, Paul Panorchan, Clare Saunders, Caroline A. Owen, Claire E. Wainwright, VX16-661-115 Investigator Group  

Ivacaftor in People With Cystic Fibrosis and a 3849+10kb C →T or D1152H Residual Function Mutation

Eitan Kerem, Malena Cohen- Cymberknoh, Reuven Tsabari, Michael Wilschanski, Joel Reiter, David Shoseyov, Alex Gileles-Hillel, Thea Pugastch, Jane C. Davies, Christopher Short, Clare Saunders, Cynthia DeSouza, James C. Sullivan, Jamie R. Doyle, Keval Chandarana, Nils Kinnman  

Utility of lung clearance index in CF: What we know, what we don't know and musings on how to bridge the gap

Christopher Short, Clare Saunders, Jane C. Davies 

Multiple breath washout in bronchiectasis clinical trials: is it feasible?

Katherine O'Neill, Kathryn Ferguson, Denis Cosgrove, Michael M. Tunney, Anthony De Soyza, Mary Carroll, James D. Chalmers, Timothy Gatheral, Adam T. Hill, John R. Hurst, Christopher Johnson, Michael R. Loebinger, Gerhild Angyalosi, Charles S. Haworth, Renee Jensen, Felix Ratjen, Clare Saunders, Christopher Short, Jane C. Davies, J. Stuart Elborn, Judy M. Bradley

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial

Felix Ratjen, Christopher Hug, Gautham Marigowda , Simon Tian, Xiaohong Huang, Sanja Stanojevic, Carlos E Milla, Paul D Robinson. David Waltz, Jane C Davies, VX14-809-109 investigator group

Entering the era of highly effective modulator therapies

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

Alex R Horsley, Jane C Davies, Robert D Gray, Kenneth A Macleod, Jackie Donovan, Zelena A Aziz, Nicholas J Bell, Margaret Rainer, Shahrul Mt-Isa, Nia Voase, Maria H Dewar, Clare Saunders, James S Gibson, Javier Parra-Leiton, Mia D Larsen, Sarah Jeswiet, Samia Soussi, Yusura Bakar, Mark G Meister, Philippa Tyler, Ann Doherty, David M Hansell, Deborah Ashby, Stephen C Hyde, Deborah R Gill, Andrew P Greening, David J Porteous, J Alastair Innes, A Christopher Boyd, Uta Griesenbach, Steve Cunningham, Eric WFW Alton

Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study

Rebecca Dobra, Stewart J. Elborn, Susan L. Madge, Lorna Allen, Marco Boeri, S Goundry, T Purcell, Clare Saunders, Jane C. Davies

bottom of page